Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 29

Results For "manufacturing"

2011 News Found

Evertis selects Honeywell Aclar technology to enhance pharmaceutical packaging
Packaging | June 11, 2025

Evertis selects Honeywell Aclar technology to enhance pharmaceutical packaging

Honeywell Aclar film technology will enable Evertis to develop high-quality barrier packaging solutions


Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites
News | June 09, 2025

Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021


Fujifilm rebrands life sciences companies to strengthen position as strategic partners for life
News | June 07, 2025

Fujifilm rebrands life sciences companies to strengthen position as strategic partners for life

Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life


Bristol Myers Squibb and BioNTech sign up to $11 billion cancer bispecific antibody collaboration
News | June 05, 2025

Bristol Myers Squibb and BioNTech sign up to $11 billion cancer bispecific antibody collaboration

BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types


Amyris expands precision fermentation line in Brazil
Biotech | June 04, 2025

Amyris expands precision fermentation line in Brazil

Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M


Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg
Drug Approval | June 02, 2025

Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg

Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)


Merck withdraws Biologics License Application for Patritumab Deruxtecan
Drug Approval | May 30, 2025

Merck withdraws Biologics License Application for Patritumab Deruxtecan

The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance


Sanjivani Paranteral posts Q4 FY25 at Rs. 2.19 Cr
News | May 28, 2025

Sanjivani Paranteral posts Q4 FY25 at Rs. 2.19 Cr

For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore